Emergency department implementation of monoclonal antibody infusion for the treatment of coronavirus disease 2019: A template for rapid deployment.
casirivimab
coronavirus disease 2019
emergency department
etesevimab
imdevimab
monoclonal antibodies
severe acute respiratory syndrome coronavirus 2
Journal
Journal of the American College of Emergency Physicians open
ISSN: 2688-1152
Titre abrégé: J Am Coll Emerg Physicians Open
Pays: United States
ID NLM: 101764779
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
26
06
2021
revised:
10
08
2021
accepted:
12
08
2021
entrez:
27
9
2021
pubmed:
28
9
2021
medline:
28
9
2021
Statut:
epublish
Résumé
Monoclonal antibody (mAb) therapy can improve coronavirus disease 2019 outcomes when infused early in select patients. We sought to rapidly create and implement a program for emergency department (ED) mAb infusion to aid care. Using multiple strategies and actions-education, selection criteria, screening tools, rapid testing, compounding, and delivery-we infused 832 ED patients with a mAb. The screening tool identified 94.5% of these patients as potential candidates. Length of stay was nearly identical for patients who tested positive for coronavirus disease 2019 versus those requiring testing. Mild adverse reactions occurred in 2.3% of mAb infusions, and severe reactions occurred in 0.5% of infusions. We highlight a strategic approach for using the ED as a key coronavirus disease 2019 therapeutic site for this intervention and with high utility and low disruption.
Identifiants
pubmed: 34568870
doi: 10.1002/emp2.12550
pii: EMP212550
pmc: PMC8448483
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e12550Informations de copyright
© 2021 The Authors. JACEP Open published by Wiley Periodicals LLC on behalf of American College of Emergency Physicians.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
JAMA. 2020 May 19;323(19):1895-1896
pubmed: 32227198
Open Forum Infect Dis. 2021 May 17;8(7):ofab254
pubmed: 34250192
N Engl J Med. 2021 Jul 14;:
pubmed: 34260849
Open Forum Infect Dis. 2021 Mar 26;8(7):ofab151
pubmed: 34322560